α(2A) adrenergic receptor promotes amyloidogenesis through disrupting APP-SorLA interaction

Yunjia Chen, Yin Peng, Pulin Che, Mary Gannon, Yin Liu, Ling Li, Guojun Bu, Thomas van Groen, Kai Jiao, Qin Wang

Research output: Contribution to journalArticle

Abstract

Accumulation of amyloid β (Aβ) peptides in the brain is the key pathogenic factor driving Alzheimer's disease (AD). Endocytic sorting of amyloid precursor protein (APP) mediated by the vacuolar protein sorting (Vps10) family of receptors plays a decisive role in controlling the outcome of APP proteolytic processing and Aβ generation. Here we report for the first time to our knowledge that this process is regulated by a G protein-coupled receptor, the α(2A) adrenergic receptor (α(2A)AR). Genetic deficiency of the α(2A)AR significantly reduces, whereas stimulation of this receptor enhances, Aβ generation and AD-related pathology. Activation of α(2A)AR signaling disrupts APP interaction with a Vps10 family receptor, sorting-related receptor with A repeat (SorLA), in cells and in the mouse brain. As a consequence, activation of α(2A)AR reduces Golgi localization of APP and concurrently promotes APP distribution in endosomes and cleavage by β secretase. The α(2A)AR is a key component of the brain noradrenergic system. Profound noradrenergic dysfunction occurs consistently in patients at the early stages of AD. α(2A)AR-promoted Aβ generation provides a novel mechanism underlying the connection between noradrenergic dysfunction and AD. Our study also suggests α(2A)AR as a previously unappreciated therapeutic target for AD. Significantly, pharmacological blockade of the α(2A)AR by a clinically used antagonist reduces AD-related pathology and ameliorates cognitive deficits in an AD transgenic model, suggesting that repurposing clinical α(2A)R antagonists would be an effective therapeutic strategy for AD.

Original languageEnglish (US)
Pages (from-to)17296-17301
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume111
Issue number48
DOIs
StatePublished - Dec 2 2014

Fingerprint

Amyloid beta-Protein Precursor
Adrenergic Receptors
Alzheimer Disease
Brain
Androgen-Insensitivity Syndrome
Pathology
Amyloid Precursor Protein Secretases
Endosomes
Protein Transport
G-Protein-Coupled Receptors
Amyloid
Pharmacology
Peptides
Therapeutics

Keywords

  • adrenergic receptor
  • amyloid
  • processing
  • SorLA
  • sorting

ASJC Scopus subject areas

  • Medicine(all)

Cite this

α(2A) adrenergic receptor promotes amyloidogenesis through disrupting APP-SorLA interaction. / Chen, Yunjia; Peng, Yin; Che, Pulin; Gannon, Mary; Liu, Yin; Li, Ling; Bu, Guojun; van Groen, Thomas; Jiao, Kai; Wang, Qin.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 111, No. 48, 02.12.2014, p. 17296-17301.

Research output: Contribution to journalArticle

Chen, Yunjia ; Peng, Yin ; Che, Pulin ; Gannon, Mary ; Liu, Yin ; Li, Ling ; Bu, Guojun ; van Groen, Thomas ; Jiao, Kai ; Wang, Qin. / α(2A) adrenergic receptor promotes amyloidogenesis through disrupting APP-SorLA interaction. In: Proceedings of the National Academy of Sciences of the United States of America. 2014 ; Vol. 111, No. 48. pp. 17296-17301.
@article{c7c6c91eb8a14fd29172c8b42888dc02,
title = "α(2A) adrenergic receptor promotes amyloidogenesis through disrupting APP-SorLA interaction",
abstract = "Accumulation of amyloid β (Aβ) peptides in the brain is the key pathogenic factor driving Alzheimer's disease (AD). Endocytic sorting of amyloid precursor protein (APP) mediated by the vacuolar protein sorting (Vps10) family of receptors plays a decisive role in controlling the outcome of APP proteolytic processing and Aβ generation. Here we report for the first time to our knowledge that this process is regulated by a G protein-coupled receptor, the α(2A) adrenergic receptor (α(2A)AR). Genetic deficiency of the α(2A)AR significantly reduces, whereas stimulation of this receptor enhances, Aβ generation and AD-related pathology. Activation of α(2A)AR signaling disrupts APP interaction with a Vps10 family receptor, sorting-related receptor with A repeat (SorLA), in cells and in the mouse brain. As a consequence, activation of α(2A)AR reduces Golgi localization of APP and concurrently promotes APP distribution in endosomes and cleavage by β secretase. The α(2A)AR is a key component of the brain noradrenergic system. Profound noradrenergic dysfunction occurs consistently in patients at the early stages of AD. α(2A)AR-promoted Aβ generation provides a novel mechanism underlying the connection between noradrenergic dysfunction and AD. Our study also suggests α(2A)AR as a previously unappreciated therapeutic target for AD. Significantly, pharmacological blockade of the α(2A)AR by a clinically used antagonist reduces AD-related pathology and ameliorates cognitive deficits in an AD transgenic model, suggesting that repurposing clinical α(2A)R antagonists would be an effective therapeutic strategy for AD.",
keywords = "adrenergic receptor, amyloid, processing, SorLA, sorting",
author = "Yunjia Chen and Yin Peng and Pulin Che and Mary Gannon and Yin Liu and Ling Li and Guojun Bu and {van Groen}, Thomas and Kai Jiao and Qin Wang",
year = "2014",
month = "12",
day = "2",
doi = "10.1073/pnas.1409513111",
language = "English (US)",
volume = "111",
pages = "17296--17301",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "48",

}

TY - JOUR

T1 - α(2A) adrenergic receptor promotes amyloidogenesis through disrupting APP-SorLA interaction

AU - Chen, Yunjia

AU - Peng, Yin

AU - Che, Pulin

AU - Gannon, Mary

AU - Liu, Yin

AU - Li, Ling

AU - Bu, Guojun

AU - van Groen, Thomas

AU - Jiao, Kai

AU - Wang, Qin

PY - 2014/12/2

Y1 - 2014/12/2

N2 - Accumulation of amyloid β (Aβ) peptides in the brain is the key pathogenic factor driving Alzheimer's disease (AD). Endocytic sorting of amyloid precursor protein (APP) mediated by the vacuolar protein sorting (Vps10) family of receptors plays a decisive role in controlling the outcome of APP proteolytic processing and Aβ generation. Here we report for the first time to our knowledge that this process is regulated by a G protein-coupled receptor, the α(2A) adrenergic receptor (α(2A)AR). Genetic deficiency of the α(2A)AR significantly reduces, whereas stimulation of this receptor enhances, Aβ generation and AD-related pathology. Activation of α(2A)AR signaling disrupts APP interaction with a Vps10 family receptor, sorting-related receptor with A repeat (SorLA), in cells and in the mouse brain. As a consequence, activation of α(2A)AR reduces Golgi localization of APP and concurrently promotes APP distribution in endosomes and cleavage by β secretase. The α(2A)AR is a key component of the brain noradrenergic system. Profound noradrenergic dysfunction occurs consistently in patients at the early stages of AD. α(2A)AR-promoted Aβ generation provides a novel mechanism underlying the connection between noradrenergic dysfunction and AD. Our study also suggests α(2A)AR as a previously unappreciated therapeutic target for AD. Significantly, pharmacological blockade of the α(2A)AR by a clinically used antagonist reduces AD-related pathology and ameliorates cognitive deficits in an AD transgenic model, suggesting that repurposing clinical α(2A)R antagonists would be an effective therapeutic strategy for AD.

AB - Accumulation of amyloid β (Aβ) peptides in the brain is the key pathogenic factor driving Alzheimer's disease (AD). Endocytic sorting of amyloid precursor protein (APP) mediated by the vacuolar protein sorting (Vps10) family of receptors plays a decisive role in controlling the outcome of APP proteolytic processing and Aβ generation. Here we report for the first time to our knowledge that this process is regulated by a G protein-coupled receptor, the α(2A) adrenergic receptor (α(2A)AR). Genetic deficiency of the α(2A)AR significantly reduces, whereas stimulation of this receptor enhances, Aβ generation and AD-related pathology. Activation of α(2A)AR signaling disrupts APP interaction with a Vps10 family receptor, sorting-related receptor with A repeat (SorLA), in cells and in the mouse brain. As a consequence, activation of α(2A)AR reduces Golgi localization of APP and concurrently promotes APP distribution in endosomes and cleavage by β secretase. The α(2A)AR is a key component of the brain noradrenergic system. Profound noradrenergic dysfunction occurs consistently in patients at the early stages of AD. α(2A)AR-promoted Aβ generation provides a novel mechanism underlying the connection between noradrenergic dysfunction and AD. Our study also suggests α(2A)AR as a previously unappreciated therapeutic target for AD. Significantly, pharmacological blockade of the α(2A)AR by a clinically used antagonist reduces AD-related pathology and ameliorates cognitive deficits in an AD transgenic model, suggesting that repurposing clinical α(2A)R antagonists would be an effective therapeutic strategy for AD.

KW - adrenergic receptor

KW - amyloid

KW - processing

KW - SorLA

KW - sorting

UR - http://www.scopus.com/inward/record.url?scp=84964315005&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964315005&partnerID=8YFLogxK

U2 - 10.1073/pnas.1409513111

DO - 10.1073/pnas.1409513111

M3 - Article

C2 - 25404298

VL - 111

SP - 17296

EP - 17301

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 48

ER -